Baseline Cytomegalovirus Immunoglobulin G Levels Predict Reactivation in Patients With Multiple Myeloma Receiving Elranatamab

ABSTRACT Background The cumulative incidence and risk of cytomegalovirus (CMV) reactivation in patients with relapsed/refractory multiple myeloma (RRMM) receiving elranatamab remain unclear. Methods We retrospectively analyzed RRMM patients treated with elranatamab to assess cumulative incidence and...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Ukyo Kondo, Taku Kikuchi, Shotaro Sugita, Miyu Watanabe, Chiaki Matsumoto, Moe Nomura‐Yogo, Kodai Kunisada, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Osamu Hosoya, Tadao Ishida, Nobuhiro Tsukada
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Wiley 2025-12-01
Schriftenreihe:	eJHaem
Schlagworte:	CMV IgG cytomegalovirus elranatamab multiple myeloma
Online-Zugang:	https://doi.org/10.1002/jha2.70189
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!